Steve Michel | Sutro Biopharma, Inc.

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created...

12th Biennial Ovarian Cancer Research Symposium – STRO-002 Poster

Presentations

12th Biennial Ovarian Cancer Research Symposium – STRO-002 Poster Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian...

Sutro Biopharma Announces $85.4 Million Series E Round

Press Releases

Sutro Biopharma Announces $85.4 Million Series E Round Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4...

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Press Releases

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has...

SutroVax Announces $85M Series C Financing led by TPG Growth

News

SutroVax Announces $85M Series C Financing led by TPG Growth SutroVax Announces $85M Series C Financing led by TPG Growth Provides growth capital to advance pneumococcal vaccine to clinic and beyond Preeminent executive vaccinologist, Moncef Slaoui, appointed Board...

« Older Entries

Next Entries »